$1.52
+0.08 (+5.56%)
Open$1.42
Previous Close$1.44
Day High$1.58
Day Low$1.40
52W High$1.72
52W Low$0.96
Volume—
Avg Volume178.1K
Market Cap34.82M
P/E Ratio—
EPS$-2.60
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+702.0% upside
Current
$1.52
$1.52
Target
$12.19
$12.19
$8.12
$12.19 avg
$14.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.46M | 3.60M | 3.02M |
| Net Income | 357.4K | 374.4K | 370.1K |
| Profit Margin | 10.3% | 10.4% | 12.2% |
| EBITDA | 792.9K | 795.7K | 655.2K |
| Free Cash Flow | 311.9K | 219.4K | 229.2K |
| Rev Growth | +0.8% | +2.8% | +23.9% |
| Debt/Equity | 0.35 | 0.28 | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |